Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with age of 20-75 years old (inclusive) in Taiwan of both genders~* Out-patients who had been diagnosed as non-erosive gastroesophageal reflux disease (NERD)~* Patients with heartburn or regurgitation (either one) as main symptom at least 2 days a week and had been present for \> or = 1 month before screening~* Patients with heartburn or regurgitation (either one) during the 7 days screening period, either with frequency for \> or = 4 days of mild symptom, or for \> or = 2 days of moderate to severe symptom~* Patients have signed the informed consent form~Exclusion Criteria:~* Patients with erosive gastroesophageal reflux disease (GERD), Barrett's esophagus or esophageal stricture~* Patients with active or healing gastroduodenal ulcer (except scars)~* Patients with history of gastric, duodenal or esophageal surgery~* Patients with malignant disease of any kind~* Patients with intrahepatic stone, gallstone, gallbladder sludge, hepatic or pancreatic carcinoma as evidenced by abdominal ultrasonography~* Patients with ischemic heart disease as evidenced by electrocardiogram~* Female patients who are pregnant or nursing mother~* Patients with a history of allergy to any of the study drugs or their related compounds~* Patients with a history of alcohol or drug abuse~* Patients with clinically significant liver disease (aspartate aminotransferase (AST), alanine aminotransferase (ALT)\>2 upper limits of normal)~* Patients with clinically significant renal disease (serum creatinine \>1.5 mg/dl)~* Patients taken a proton pump inhibitor (PPI) within 14 days before screening, or a H2-blocker, prokinetic agent or antacid within 7 days before screening~* Patients participated any investigational drug trial within 4 weeks before screening~* Patients with any other conditions or diseases that investigator considers it is not appropriate to enter the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sodium alginate (Type: EXPERIMENTAL): Oral suspension, 50 mg/ml
- Omeprazole (Type: ACTIVE_COMPARATOR): 20 mg/cap

Based on this trial design, predict the completion outcome and termination type (if applicable).